Growth Metrics

Moderna (MRNA) Gains from Investment Securities (2018 - 2025)

Moderna (MRNA) has disclosed Gains from Investment Securities for 8 consecutive years, with $25.0 million as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities rose 118.52% to $25.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.0 million through Dec 2025, up 143.33% year-over-year, with the annual reading at $26.0 million for FY2025, 143.33% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $25.0 million at Moderna, up from $9.0 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $96.0 million in Q3 2021, with the low at -$135.0 million in Q4 2024.
  • Average Gains from Investment Securities over 5 years is -$3.8 million, with a median of -$3.0 million recorded in 2023.
  • Peak annual rise in Gains from Investment Securities hit 541.18% in 2024, while the deepest fall reached 1828.57% in 2024.
  • Over 5 years, Gains from Investment Securities stood at -$96.0 million in 2021, then surged by 108.33% to $8.0 million in 2022, then tumbled by 187.5% to -$7.0 million in 2023, then plummeted by 1828.57% to -$135.0 million in 2024, then skyrocketed by 118.52% to $25.0 million in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $25.0 million, $9.0 million, and -$9.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.